578729-19-8Relevant articles and documents
Development of orally bioavailable and CNS penetrant biphenylaminocyclopropane carboxamide bradykinin B1 receptor antagonists
Kuduk, Scott D.,Di Marco, Christina N.,Chang, Ronald K.,Wood, Michael R.,Schirripa, Kathy M.,Kim, June J.,Wai, Jenny M. C.,DiPardo, Robert M.,Murphy, Kathy L.,Ransom, Richard W.,Harrell, C. Meacham,Reiss, Duane R.,Holahan, Marie A.,Cook, Jacquelynn,Hess, J. Fred,Sain, Nova,Urban, Mark O.,Tang, Cuyue,Prueksaritanont, Thomayant,Pettibone, Douglas J.,Bock, Mark G.
, p. 272 - 282 (2007/10/03)
A series of biphenylaminocyclopropane carboxamide based bradykinin B 1 receptor antagonists has been developed that possesses good pharmacokinetic properties and is CNS penetrant. Discovery that the replacement of the trifluoropropionamide in t